On August 9, Yuanda Pharmaceutical disclosed that the company's FAP target innovative nuclear drug GPN01530-2 was granted fast track qualification by the US FDA. GPN01530-2 has now been approved by the FDA to carry out phase I/II clinical studies to diagnose solid tumors. This fast-track qualification is expected to accelerate the future development and marketing process of GPN01530-2.

On August 9, Yuanda Pharmaceutical disclosed that the company's FAP target innovative nuclear drug GPN01530-2 was granted fast track qualification by the US FDA. GPN01530-2 has now been approved by the FDA to carry out phase I/II clinical studies to diagnose solid tumors. This fast-track qualification is expected to accelerate the future development and marketing process of GPN01530-2.